AnaptysBio (ANAB) was upgraded by Guggenheim from a “neutral” rating to a “buy” rating in a note issued to investors on Wednesday.
Several other brokerages have also recently issued reports on ANAB. BidaskClub raised shares of AnaptysBio from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 17th. Zacks Investment Research upgraded shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Monday, June 22nd. Two analysts have rated the stock with a sell rating, five have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $16.83.
AnaptysBio last released its earnings results on Monday, August 10th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.04). As a group, sell-side analysts expect that AnaptysBio will post -2.05 earnings per share for the current fiscal year.
AnaptysBio is a clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from collaborative research and development arrangements.
Should you invest in AnaptysBio (ANAB)
Shares of AnaptysBio (ANAB) appear to be a very good investment option, the Money Midnight Indicator is expecting its price to increase considerably in the years to come. The majority of the metrics point to this investment being highly attractive.
